

Analytical precision performance evaluation of selected immunoassays on the immunochemistry analytical unit of cobas pure integrated solutions

Christian Schneider-Thauern¹, Boris Pinchuk¹, Hannsjörg Baum², Nico Vogt², Peter Findeisen³, Anna Krajewska⁴, Dawid Radziszewski⁴, Maria Umlauf¹

M030

¹Roche Diagnostics GmbH, Mannheim/Penzberg, Germany; ²Institut für Laboratoriumsmedizin und Transfusionsmedizin, Regionale Kliniken Holding RKH, Ludwigsburg, Germany; ³MVZ Limbach, Heidelberg, Germany; ⁴Diagnostyka Sp. z o.o., Wrocław, Poland

Introduction

- cobas[®] pure integrated solutions (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) is a serum work area laboratory analyser consolidating clinical chemistry/ion selective electrolyte (cobas c 303) and immunochemistry (cobas e 402) testing in plasma, serum and urine on a single platform.
- cobas pure integrated solutions was developed as a successor to cobas 6000 (cobas c 501 and e 601); however, the system is more compact with footprint of two square metres.
- The immunochemistry unit of cobas pure integrated solutions (cobas e 402) is an alternative to the cobas e 602 and e 801 analysers.

Objectives

- We conducted a multicentre study to evaluate the precision performance of selected immunoassays on cobas pure integrated solutions versus cobas legacy systems.

Methods

- Precision experiments based on the Clinical and Laboratory Standards Institute EP05-A3 protocol were conducted at three external sites (Ludwigsburg/Heidelberg, Germany; Wrocław, Poland) and one internal site (Penzberg, Germany) during May–June 2021.
- There were two runs per day for ≥5 days per instrument; for each sample and run, a single determination of three separate aliquots per sample was performed.

Results

Distribution of precision

- Of the 79 samples tested, precision was calculated for 78 samples; one sample tested using the Anti-HBs II immunoassay demonstrated analyte recovery below the measuring range and was therefore excluded from the analysis.
- Of the 78 results, 30 samples recovered at a low analyte concentration level. The remaining 48 samples recovered at medium or high analyte concentration levels (Table 2).

Table 2. Distribution of repeatability, intermediate precision and reproducibility CVs


CV range, %	Repeatability, n (%)		Intermediate precision, n (%)		Reproducibility, n (%)	
	All samples*	Medium/high†	All samples	Medium/high	All samples	Medium/high
<2.5	57 (73)	40 (83)	38 (49)	29 (60)	17 (22)	17 (35)
2.5–<5	14 (18)	6 (13)	24 (31)	13 (27)	37 (47)	21 (44)
5–<10	7 (9)	2 (4)	14 (18)	5 (10)	19 (24)	9 (19)
10–<15	0 (0)	0 (0)	2 (3)	1 (2)	4 (5)	1 (2)
≤16	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Total	78 (100)	48 (100)	78 (100)	48 (100)	78 (100)	48 (100)

*Of the 79 samples tested, precision was calculated for 78 samples. †Samples recovered at medium/high analyte concentration levels (n=48).

Samples close to the medical decision point (MDP)

- Precision performance in samples with analyte concentration close to the MDP on cobas pure integrated solutions was comparable to, or better than, the legacy systems (Figure 1).
- CVs for repeatability around the MDP or cut-off value for cobas pure integrated solutions ranged from 0.9% (HBeAg) to 4.7% (HBsAg II); those for intermediate precision ranged from 1.3% (anti-HBc II) to 6.5% (anti-HBs II), and for reproducibility they ranged from 2.3% (total PSA) to 8.9% (anti-HBc IgM).

Figure 1. Precision results for samples close to the medical decision point



Methods (continued)

- Samples included Roche-produced Elecsys[®] quality control (QC) materials (low and high analyte concentration) and anonymised human serum sample pools covering the respective assay measuring ranges (negative and positive).
 - Identical samples (N=79) and reagents were used at each site.
- Comparator legacy systems included in the study were cobas e 601, e 602 and e 801; nine routine immunoassays were studied (Table 1).
- Coefficients of variation (CVs) for repeatability and intermediate precision (per site), and reproducibility (across all sites) were calculated and compared with pre-defined acceptance criteria.

Table 1. Comparator legacy systems and immunoassays studied


New system	Legacy systems	Immunoassay
cobas pure integrated solutions (cobas e 402)	cobas e 601	Anti-HBs II HBsAg II Anti-HCV II Anti-HBc IgM Anti-HBc II
	cobas e 602	Anti-HBe
	cobas e 801	free PSA total PSA HBeAg

Anti-HBc, antibody to hepatitis B core antigen; Anti-HBe, antibody to hepatitis B e antigen; Anti-HBs, antibody to hepatitis B surface antigen; Anti-HCV, antibody to hepatitis C virus; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; IgM, immunoglobulin M; PSA, prostate-specific antigen.

Low and high concentration QC samples

- Precision performance in QC low and high concentration samples across a range of immunoassays on cobas pure integrated solutions was comparable to, or better than, the legacy analysers (Figure 2).

Figure 2. Precision results for (A) low and (B) high concentration QC samples



*Anti-HBs II demonstrated analyte recovery below the measuring range and was therefore excluded from the analysis.

Conclusions

- The analytical precision performance of cobas pure integrated solutions for a selected panel of immunoassays was comparable to, or better than, the precision performance of the Roche legacy analysers.
- These observations support the implementation of the immunochemistry analytical unit of cobas pure integrated solutions into routine clinical laboratory practice, and provide evidence to suggest that there should be a seamless transition from the legacy systems to the new system.

Disclosures

This study was funded by Roche Diagnostics International Ltd (Rotkreuz, Switzerland). Third-party medical writing support, under the direction of the authors, was provided by Sophie Lavelle, MSc, of Ashfield MedComms (Macclesfield, UK), an Ashfield Health company, and was funded by Roche Diagnostics International Ltd (Rotkreuz, Switzerland). COBAS, COBAS C, COBAS E, COBAS PURE and ELECSYS are trademarks of Roche.